Review article

Epileptic Disord 2005; 7 (3): 181-92

Chromosomal disorders associated with epilepsy

Agatino Battaglia¹, Renzo Guerrini^{1,2}

¹ Stella Maris Clinical Research Institute for Child and Adolescent Neuropsychiatry, Calambrone, Pisa

² Department of Developmental Neurosciences, University of Pisa, Italy

Received April 27, 2005; Accepted June 10, 2005

ABSTRACT – Epilepsy is among the most common findings associated with chromosome aberrations, particularly those involving autosomal chromosome imbalances. Most chromosome aberrations can be associated with different seizure types, but there are a few aberrations featuring specific seizure and electroencephalographic (EEG) patterns. The analysis of electro-clinical patterns associated with chromosomal aberrations is a major tool in the identification of epilepsy susceptibility genes. Advances in molecular cytogenetic techniques will certainly increase the diagnostic yield, and an increasing number of individuals previously diagnosed as having "cryptogenic" epilepsy will turn out to have an underlying chromosomal aberration. We review the types of seizures, EEG findings, and their natural history in the chromosomal disorders that are consistently associated with epilepsy.

Key words: chromosomal disorders, malformation syndromes, epilepsy, seizures

Epilepsy is among the most common findings associated with chromosome aberrations, particularly those involving autosomal chromosome imbalance. Virtually all known chromosomal abnormalities lead to anatomofunctional impairment of the central nervous system and most are accompanied by developmental delay and mental retardation. Although the risk of epilepsy is greater in individuals with chromosomal disorders than in the general population (Holmes 1987) such genetic disorders do not represent per se, a frequent cause of epilepsy (Jennings and Bird 1981). Most chromosome aberrations can be associated with a variety of seizure types, but there are certain aberrations featuring specific seizure and electroencephalographic (EEG) patterns. Despite the increasing interest in the genetics of epilepsy, little attention has been paid to cytogenetics as a resource with which to identify putative epilepsy genes. The analysis of electro-clinical patterns associated with chromosomal aberrations is a major tool in the identification of epilepsy susceptibility genes. Advances in molecular cytogenetic techniques, such as fluorescent in situ hybridization (FISH), subtelomeric analysis, and comparative genomic hybridization (CGH) microarray, have great diagnostic potential, allowing for the detection of submicroscopic or "cryptic" chromosome rearrangements. Such recent laboratory methods will certainly increase the diagnostic yield, and a number of individuals previously diagnosed as having "cryptogenic" epilepsy will turn out to have a causative chromosomal aberration.

Chromosome aberrations may be caused by abnormalities in number or structure. Abnormalities of chromosome number include polyploidy, and autosomal and sex chromosome aneuploidy. Aneuploides of the auto-

Correspondence:

A. Bataglia, MD Stella Maris Clinical Research Institute for Child and Adolescent Neuropsychiatry, via dei Giacinti, 2 56018 Calambrone (Pisa), Italy Tel.: (+ 00 39) 050 886248 Fax: (+ 00 39) 050 32214 <agatino.battaglia@inpe.unipi.it> somes are among the most clinically important of the chromosome abnormalities. Aneuploides consist primarily of "monosomy" (the presence of only one copy of a chromosome in an otherwise diploid cell) and "trisomy" (three copies of a chromosome). Abnormalities of chromosome structure consist primarily of translocations (interchange of genetic material between nonhomologous chromosomes); deletions (caused by a chromosome break and subsequent loss of genetic material); and duplications (partial trisomy of genetic material) (Jorde *et al.* 2003).

Accurate information on the epilepsy phenotype, specific electroclinical findings and their natural history is of paramount importance to pediatricians and child neurologists who provide health care to patients with epilepsy associated with chromosome aberration. Here, we present a review of the most common chromosomal disorders that are consistently associated with epilepsy.

Del 1p36 syndrome

The del 1p36 syndrome is a recently characterised clinical entity, associated with distinct congenital anomalies and mental retardation. The incidence is estimated to be 1 in 5,000 to 1 in 10,000, making it the most common terminal deletion (Shaffer and Heilstedt 2001). There seems to be a female predilection of 1.5:1 (Heilstedt et al. 2003, Battaglia et al. 2004). About 100 cases have been reported (Heilstedt et al. 2003, Magenis et al. 1987). Monosomy 1p36 may be the result of pure terminal deletions, interstitial deletions of varying sizes and different breakpoints (Wu et al. 1999) derivative chromosome 1, or more complex rearrangements (Heilstedt et al. 2003, Battaglia et al. 2004). Conventional cytogenetics may not detect these different rearrangements, particularly those that are derivative chromosomes. FISH analysis with subtelomeric, region-specific probes is necessary in most cases. Determination of the parental origin has shown discordant results. In one series, 24/40 (60%) of de novo 1p36, terminal deletions arose from the maternally inherited chromosome (Heilstedt et al. 2003), whereas in another study, 4/5 (80%) terminal deletions arose from the paternally inherited chromosome (Battaglia et al. 2004). Overall, deletions of paternal origin seem to be larger than deletions derived from the maternally inherited chromosome (Heilstedt et al. 2003, Battaglia et al. 2004). Preand/or postnatal growth retardation (Magenis et al. 1987, Yunis et al. 1981, Blennow et al. 1996, Reish et al. 1995, Keppler-Noreuil et al. 1995, Giraudeau et al. 1997, Shapira et al. 1997, Riegel et al. 1999, Hain et al. 1980, Biegel et al. 1993, Slavotinek et al. 1999), as well as obesity and hyperphagia (Keppler-Noreuil et al. 1995, Sandlin et al. 1995, Shapira et al. 1997, Eugster et al. 1997) have been reported.

The craniofacial features of these individuals are distinct and remarkably similar, representing a hallmark of the condition. They include: micro-brachycephaly; large and late-closing anterior fontanelle; prominent forehead; straight eyebrows; deep-set eyes; short palpebral fissures; broad/flat nasal bridge; midface hypoplasia; pointed chin; abnormal ears.

All subjects have developmental delay/mental retardation varying from moderate to profound (Shaffer and Heilstedt 2001, Heilstedt *et al.* 2003, Battaglia *et al.* 2004, Shapira *et al.* 1997). Expressive language is significantly impaired, being absent or very poor in most. However, three patients with the smallest documented deletions had mild mental retardation and complex speech abilities (Wu *et al.* 1999, Slavotinek *et al.* 1999). The craniofacial features, together with the neurodevelopmental manifestations, should prompt clinical recognition of the syndrome.

Seizures occur in about 50% of patients (Heilstedt et al. 2003, Battaglia et al. 2004). There does not appear to be one seizure type that is predominant, and infantile spasms, simple and complex partial seizures, generalized tonicclonic seizures, myoclonic seizures, and absence spells have been reported (Blennow et al. 1996, Reish et al. 1995, Slavotinek et al. 1999, Keppler-Noreuil et al. 1995, Giraudeau et al. 1997, Shapira et al. 1997, Riegel et al. 1999, Knight-Jones et al. 2000). Age at seizure-onset is difficult to retrieve from the literature. However, from the available data it appears that seizures start in infancy or childhood, and are well controlled by antiepileptic drugs (Battaglia et al. 2004, Eugster et al. 1997, Slavotinek et al. 1999). EEG abnormalities are also variable, including hypsarrhythmia, focal and multifocal spikes, and asymmetry of slow wave activity (Battaglia et al. 2004, Knight-Jones et al. 2000, Wenger et al. 1988).

Of note, a severe seizure phenotype (including infantile spasms and medically intractable seizures) or epileptiform activity on the EEG has been associated with hemizygosity for the voltage-gated K⁺ channel β -subunit gene, *KCNAB2* (Heilstedt *et al.* 2001).

Cerebral atrophy, ventricular dilatation/asymmetry, hydrocephalus, delay in myelination, focal cortical dysplasia, and a leukodystrophic picture have been documented on brain neuroimaging (Battaglia *et al.* 2004, Yunis *et al.* 1981, Keppler-Noreuil *et al.* 1995, Shapira *et al.* 1997, Riedel *et al.* 1999, Hain *et al.* 1980, Slavotinek *et al.* 1999, Heilstedt *et al.* 2001, Faivre *et al.* 1999, Battaglia 2005a).

Del 4p (Wolf-Hirschhorn) syndrome

Wolf-Hirschhorn syndrome (WHS) is a well-known, multiple congenital anomalies/mental retardation syndrome (Cooper and Hirschhorn 1961). Its frequency is estimated as one per 50,000 births, with a female predilection of 2:1 (Lurie *et al.* 1980, Gorlin *et al.* 1990). However, it is possible that this rate is an underestimation in view of the frequency of missed diagnosis due to lack of recognition or inadequate cytogenetic analysis (Battaglia *et al.* 2001). The disorder is caused by partial loss of material from the distal portion of the short arm of chromosome 4. The minimal deleted segment causing the phenotype is 4p16.3 (Lurie *et al.* 1980). While most individuals (75%) have a *de novo* deletion (Lurie *et al.* 1980) of preferential paternal origin (Tupler *et al.* 1992, Dallapiccola *et al.* 1993), about 12% have an unusual chromosome abnormality (such as ring 4), and about 13% have deletion of 4p16 as the result of having inherited an unbalanced chromosome rearrangement from a parent with a balanced rearrangement. Standard cytogenetics detects about 60-70% of deletions, while FISH (using the WHSCR probe) detects > 95%. Subtelomeric FISH analysis can be useful to determine if a deletion is the result of an unbalanced translocation (Battaglia *et al.* 2002-2004).

The most striking features of del 4p are the typical "Greek warrior helmet appearance of the nose" (*i.e.* the broad bridge of the nose continuing to the forehead), pre and post-natal growth delay, congenital hypotonia, mental retardation and seizures (Battaglia *et al.* 2001).

According to different reports, epileptic seizures constitute a major medical concern during the first years of life, and occur in 50% to 100% of WHS patients (Battaglia et al. 2001, Guthrie et al. 1971, Centerwall et al. 1975, De Grouchy and Turleau 1984, Stengel-Rutkowski et al. 1984). These seizures usually begin within the first two years of life, with a peak incidence at around 9-10 months of age. They may be clonic or tonic, unilateral with or without secondary generalisation, or generalised as tonicclonic from the onset (Battaglia et al. 2001, Reid et al. 1996, Estabrooks et al. 1994, Ogle et al. 1996, Battaglia 1997, Battaglia et al. 1999a, Battaglia et al. 1999b, Battaglia and Carey 1999, Battaglia and Carey 2000). They are frequently triggered by fever; may last 15 minutes or longer, and often occur in clusters (Battaglia 1997, Battaglia et al. 1999a and b, Sgrò et al. 1995, Zankl et al. 2001). In over 50% of the patients, unilateral or generalised clonic or tonic-clonic status epilepticus occurs during the early years, despite adequate antiepileptic treatment (Battaglia et al. 2001). Between 1 and 5 years of age, almost two thirds of the patients develop atypical absences, often accompanied by a mild myoclonic component, mainly involving the eyelids and axorizomelic muscles (Battaglia et al. 2001, Battaglia et al. 2004, Battaglia 1997, Battaglia et al. 1999, Battaglia et al. 1999, Sgrò et al. 1995). These episodes are accompanied by generalised slow spike/wave complexes. Interictal EEG shows high amplitude, fast spikes-polyspikes/wave complexes over the posterior temporal and parieto-occipital regions, triggered by eye closure. Other seizure types associated with del 4p have been described in a minority of patients, and include myoclonic seizures (Zankl et al. 2001), tonic spasms, and complex partial seizures (Kanazawa et al. 1991).

In our experience, the seizures observed in WHS can be effectively controlled by valproate (VPA) alone or associated with ethosuximide (ESM). In a minority of patients there may be a need to add a benzodiazepine (Battaglia and Carey, in preparation). However, the use of carbamazepine (CBZ) may worsen the electroclinical picture. Despite early severity, the long term outcome of epilepsy seems to be good, as seizures tend to disappear with age (Battaglia 2005b, Battaglia and Carey 2005). The GABA_A receptor gene was a candidate gene for epilepsy in WHS. However, this gene maps proximal to the critical deletion region (WHSCR), specifically, 4p12-p13 (Buckle et al. 1989). Whereas, LETM1, a gene possibly involved in Ca²⁺ signalling or homeostasis, seems to be a good candidate for the seizures and neuromuscular problems in WHS (Endele et al. 1999, Van Buggenhout et al. 2004). Initially, LETM1 was suggested to flank the WHSCR (Battaglia et al. 2001, Endele et al. 1999), but a recent report implies that it falls within the newly proposed critical region of WHS, nearer the telomere (Zollino et al. 2003).

The most frequent brain abnormality is corpus callosum hypoplasia, occasionally associated with decreased white matter volume, and hypoplasia or agenesis of the posterior lobe of the cerebellum. Hypoplastic brain with narrow gyri, heterotopias, and dysplasias of nuclear structures have been described in a minority of cases (Lazjuk *et al.* 1980, Gottfried *et al.* 1981).

Trisomy 12p syndrome

Just over twenty cases of duplication of the short arm of chromosome 12 have been reported (Schinzel 2001). Trisomy 12p is estimated to occur at a rate of 1 to 50,000 births (Stengel-Rutkoswki *et al.* 1981). The patient's face shows some similarity to Down syndrome, and, in addition, turri-brachycephaly, bushy eyebrows, hypoplastic philtrum, everted lower lip, full cheeks, short hands and club feet can be present. Mental retardation is usually severe.

Most cases of trisomy 12p are due to familial translocations; a minority occur as a *de novo* isochromosome with translocation (Allen *et al.* 1996) or as a *de novo* translocation (Ray *et al.* 1985).

Lateralized microgyria, internal hydrocephalus, cortical dysplasia and ectopic glial tissue in the leptomeninges have been observed at neuropathology examination, in three neonates with severe malformations (Nielsen *et al.* 1977).

Description of seizures has been very scant. Generalised convulsive seizures, on occasions triggered by fever, or myoclonic seizures are the most frequently reported. Of note, is the occurrence of generalised 3 Hz spike/wave complexes in 4 patients, 3 of whom had childhood-onset myoclonic absences or myoclonic seizures, which were well controlled by AEDs (Guerrini *et al.* 1990, Elia *et al.* 1998).

Ring chromosome 14 syndrome

Ring chromosome 14 (r14), is a rare chromosomal disorder, reported so far in more than 30 patients, and consistently associated with seizures. In all cases, dysmorphic features are mild, and almost invariably seizures occur in infancy and are intractable (Schinzel 2001, Singh et al. 2002). A variety of types has been described, including generalized tonic-clonic, myoclonic, complex partial seizures, and "minor motor" seizures (Lippe and Sparkes 1981, Schmidt et al. 1981, Fryns et al. 1983, Matalon et al. 1990, Zelante et al. 1991). Brain atrophy with ventricle dilatation has been observed in several subjects. The degree of mental impairment varies from mild to severe. In most individuals the breakpoints in 14q were detected in the terminal band 14q32. Familial occurrence has been noted in two instances (Matalon et al. 1990, Riley et al. 1981).

Angelman syndrome

Angelman syndrome (AS) has emerged as an important neurogenetic disorder due to its incidence of about 1/12,000-20,000 (Steffenburg *et al.* 1996), and easier confirmation of the diagnosis by improved genetic testing. Owing to its nonspecific clinical features, AS poses diagnostic challenges to the clinician during the first years of life. In later childhood however, developmental delay/ mental retardation, absent or very poor speech (<10 words), ataxia, jerky movements, and the happy countenance with frequent laughter usually present as a recognisable clinical entity.

AS results from the absence or nonfunctioning of the normally active maternal allele at 15q11-q13.

From 70 to 75% of subjects show a deletion of region 15q11-q13 of the maternally-derived chromosome; 2-5% show paternal uniparental disomy (UPD) of chromosome 15; 2-5% have an imprinting centre (IC) defect; 20-25% show *UBE3A* and other presumed, single gene mutations. A few individuals with the apparent clinical phenotype of AS have no, as yet detectable genetic abnormality.

The suggested first line testing is either FISH (plus a standard karyotype) or DNA methylation analysis. Methylation analysis will diagnose 80% of patients with classic AS, but when this is the first investigation, further evaluation with FISH and/or DNA polymorphism analysis is recommended to identify the molecular class of AS (deletion; UPD; IC defect), for genetic counseling purposes (Williams 2005). *UBE3A* gene mutation analysis should be pursued when there is a strong clinical suspicion of AS and a negative methylation test. The rare cases of familial recurrence of AS show either IC or *UBE3A* mutations (Guerrini *et al.* 2003).

All patients have severe developmental delay/mental retardation, becoming apparent by age 6-12 months; absent or very poor speech; ataxic gait; tremulousness of limbs; and a distinct behavior profile with unprovoked and frequent laughter, excitable personality, hand flapping, and short attention span. Microcephaly becomes evident by age 2 years. Additional, less frequent findings have also been reported (Battaglia and Gurrieri 1999). Neuroimaging usually shows a structurally normal brain. However, small temporal and frontal lobes with disorganized and irregular gyri, irregular distribution of neurons in layer 3, and minor heterotopias in both the cerebrum and cerebellum have been reported in two patients (Jay *et al.* 1991, Kyriakides *et al.* 1992).

Epilepsy is very frequent, affecting as much as 90% of children (Angelman 1965, Matsumoto et al. 1992, Viani et al. 1995, Zori et al. 1992). Apparently, fewer than 25% of patients develop seizures before age 1 year; most starting before age 3. Initial occurrence later in life is not infrequent (Matsumoto et al. 1992, Viani et al. 1995, Zori et al. 1992, Sugimoto et al. 1994). The first seizures are often precipitated by fever (Matsumoto et al. 1992, Sugimoto et al. 1994). Atypical absences, myoclonic seizures, generalised tonic-clonic and unilateral seizures are among the main ictal patterns (Battaglia and Gurrieri 1999, Matsumoto et al. 1992, Viani et al. 1995, Sugimoto et al. 1994). Complex partial seizures with eye deviation and vomiting, possibly indicating occipital lobe origin, seem to occur frequently (Viani et al. 1995), whereas infantile spasms with hypsarrhythmia are exceptional. Over half the subjects suffer from episodes of decreased alertness and hypotonia, lasting for days or weeks, described as nonconvulsive status epilepticus (Matsumoto et al. 1992, Sugimoto et al. 1994). Often a concomitant mild jerking (Dalla Bernadina et al. 1992, Guerrini et al. 1996) may be observed. Video-EEG-polygraphic recordings during myoclonic status or short myoclonic seizures show diffuse, irregular, 2 Hz spike/wave complexes, accompanied in some patients by EEG-spikes that are time-locked to myoclonic potentials. Myoclonic jerks typically cease during sleep (Viani et al. 1995, Guerrini et al. 1996) and, in some patients, may remain erratic, with no apparent relation to the EEG discharges. In addition, AS patients exhibit quasicontinuous, 11 Hz, multifocal, rhythmic cortical myoclonia, mainly involving the hands and face, which are responsible for mild jerking or twitching, easily mistaken for a tremor (Guerrini et al. 1996).

Although initially rather difficult to treat, seizures often remit after puberty (Matsumoto *et al.* 1992, Bower and Jeavons 1967, Boyd *et al.* 1988), and myoclonic status is rare after age 6, providing additional support for agedependence of seizure expression (Zori *et al.* 1992). Complete seizure remission is however, rare (Laan *et al.* 1997, Minassian *et al.* 1998), the number of subjects still having seizures as adults being unknown.

Subjects with AS have distinctive EEG patterns varying with age (Matsumoto *et al.* 1992, Viani *et al.* 1995, Sugimoto *et al.* 1994, Boyd *et al.* 1988, Laan *et al.* 1997,

Minassian *et al.* 1998). The most characteristic consists of interictal bursts of high amplitude 1-3 c/s bilateral anterior slow waves, which tends to diminish with age (Matsumoto *et al.* 1992).

Myoclonic status epilepticus, although frequently relapsing (Matsumoto *et al.* 1992), is well controlled by intravenous benzodiazepines (BDZs) (Viani *et al.* 1995, Guerrini *et al.* 1996) or by VPA in association with ethosuccimide (ESM) (Dalla Bernadina *et al.* 1992). Nonconvulsive status epilepticus is also well controlled by *i.v.* benzodiazepines (Viani *et al.* 1995, Guerrini *et al.* 1996). The association of clobazam-valproic acid (VPA) is particularly effective for long-term treatment (Viani *et al.* 1995, Guerrini *et al.* 1996), whereas carbamazepine (CBZ) or vigabatrin (GVG) may increase both myoclonia and absence seizures (Viani *et al.* 1995, Kuenzle *et al.* 1998). Cortical myoclonia, when particularly disabling, may respond best to piracetam in high doses (Guerrini *et al.* 1996).

Among the genes residing in the deleted region are the *UBE3A* and three GABA_A receptor subunits (β 3, α 5, γ 3). *UBE3A* is imprinted in brain but not in other tissues, a finding that is compatible with the brain being the most affected organ in AS (Rougelle *et al.* 1997). Patients with the large 15q11-q13 deletion show a more severe electroclinical picture than those with UPD (Minassian *et al.* 1998). This observation suggests that one or more genes in the deleted region, including the GABA receptor subunit genes, may modify the AS phenotype caused by the lack of maternal *UBE3A* function. A possible mechanism for the seizures is dysfunction of GABA_A receptor subunits.

Inv-dup (15) or Idic (15) syndrome

The chromosome region 15q11-q13 is known for its instability (Donlon et al. 1986), and many rearrangements may occur in this imprinted segment, including deletions, translocations, inversions, and supernumerary marker chromosomes formed by the inverted duplication of proximal chromosome 15. Interstitial duplications and triplications are much less frequent. The inv dup(15) is the most common of the heterogeneous group of extra-structurally abnormal chromosomes (ESACs), and accounts for about 50% of supernumerary marker chromosomes (Hook and Cross 1987). Of the two identified cytogenetic types of inv dup(15) marker chromosomes, one is a metacentric, smaller or similar to a G group chromosome, not containing the PWS/AS critical region (PWS/ASCR), and is found in children with a normal phenotype (Cheng et al. 1994). The second type of inv dup(15) is as large as or larger than a G group chromosome, contains the PWS/AS critical region (Robinson et al. 1993, Blennow et al. 1995), and is associated with an abnormal phenotype (Battaglia et al. 1997). Its cytogenetic description is dic(15)(q12 or q13). Most dic(15)(q12 or q13) derive from the two homologous

maternal chromosomes at meiosis, and are associated with increased maternal age at conception. The presence of large inv dup(15) results in tetrasomy 15p and partial tetrasomy 15q. Incidence at birth is estimated as 1 to 30,000 with a sex ratio of 1 (Schinzel and Niedrist 2001). In order to detect the rearrangement, standard cytogenetics must be associated with FISH analysis, with probes both from proximal chromosome 15 and from the PWS/ASCR (Luke et al. 1994, Webb et al. 1998). For detection of parent-of-origin, microsatellite analysis of parental DNA, or methylation analysis of the proband DNA are also needed (Luke et al. 1994, Webb et al. 1998). The most consistent clinical findings are represented by moderate-profound developmental delay/mental retardation, severe epilepsy, diffuse hypotonia, and autistic behavior (Battaglia et al. 1997, Cabrera et al. 1998, Borgatti et al. 2001, Takeda et al. 2000, Battaglia 2005c). Overall, there are either no dysmorphic findings or only "minor anomalies", such as epicanthus, downslanting of the palpebral fissures, low-set ears, and skin pigmentary changes.

In most individuals, epilepsy shows the characteristics of the Lennox-Gastaut syndrome or of a similar syndrome, with very poor outcome. West syndrome has been reported in a minority of subjects (Battaglia et al. 1997, Cabrera et al. 1998, Takeda et al. 2000, Battaglia 2005c, Torrisi et al. 2001). Myoclonic and complex partial seizures have also been observed (Gillberg et al. 1991, Aguglia et al. 1999). A milder clinical presentation with adult-onset generalized epilepsy has been reported in two patients with large inv dup(15) (Chifari et al. 2002). Various genetic mechanisms have been hypothesized to explain clinical heterogeneity, beyond the size of chromosomal duplication, including dosage effect of genes located within the duplicated region (Battaglia 2005c, Torrisi et al. 2001). Considering that a mild epileptic phenotype does not rule out a diagnosis of inv dup(15), it has been suggested that such a chromosome rearrangement be ruled out as a possible, though rare, cause of atypical "cryptogenic" or idiopathic generalized epilepsy (Chifari *et al.* 2002).

Ring chromosome 20 syndrome

Ring chromosome 20 (r20) is a rare chromosomal disorder, of which epilepsy is a striking feature. Conversely, the absence of a consistent pattern of dysmorphic signs, and very rare malformations, makes the diagnosis difficult. Psychomotor development tends to be initially normal. Seizures occur in almost all subjects, with onset between infancy and age 17, and tend to be refractory to treatment (Singh *et al.* 2002, Zuberi and Biraben 2004). The distinct electro-clinical pattern is represented by a "nonconvulsive status" with repetitive, prolonged episodes of confusion, speech difficulties and complex automatisms,

usually lasting from several minutes to one hour, accompanied by continuous, 2-3 Hz, bilateral, high amplitude slow waves with occasional spikes, with frontal predominance. Such episodes often occur daily, and can be interspersed with perioral jerking and eyelid myoclonia (Singh et al. 2002, Lancman et al. 1993, Inoue et al. 1997, Petit et al. 1999, Canevini et al. 1998). Typical spike and wave discharges are rarely seen. Frontal lobe ictal-onset was shown by means of subdural electrodes during typical confusional episodes (Inoue et al. 1997). On the basis of ictal SPECT studies, a possible role for subcortical structures in the genesis of such a characteristic ictal pattern has been hypothesized (Biraben et al. 2001). Hyperventilation, specific mental activities or adverse psychological situations play a triggering role in some children (Roubertie et al. 2000). Prolonged seizures are still at risk of being misinterpreted as behavioral, non-epileptic manifestations, particularly in young children, unless video-EEG recording is available (Inoue et al. 1997). Partial motor, complex partial and generalized tonic-clonic seizures have also been reported. Interictal EEG, normal in some individuals, can show spikes over both fronto-temporal regions in others.

The description of more than 30 cases has highlighted the uniqueness of the electro-clinical presentation of the r20 syndrome (Singh et al. 2002), which should always prompt a request for karyotyping. In view of the fact that the percentage of lymphocytes carrying the chromosome rearrangement may be low, this analysis should be performed looking at, at least, 100 mitoses (Roubertie et al. 2000). In most cases the locus of fusion between the deleted short and long arms in the ring chromosome was p13q13 or p13q13.3 or p13q13.33 (Singh et al. 2002, Inoue et al. 1997). The loss of telomeric material on both arms of chromosome 20 is usually identified by FISH (Brandt et al. 1993). Cases with a mosaicism for r20 have also been observed. Most cases are sporadic, but a few are familial (Canevini et al. 1998). The severity of cognitive impairment seems to correlate with the percentage of mosaicism, whereas that of epilepsy does not (Inoue et al. 1997).

Trisomy 21 (Down's) syndrome

Down's syndrome (DS) has an incidence of about 1/650 to 1/1,000 live births (Smith and Berg 1976). It is associated with triplication of chromosomes 21 in 95% of individuals; with chromosomal translocation in 4%; and with mosaicism of a trisomic cell line in 1%. The full phenotype appears to manifest when band 21q22 is triplicated, subband 21q22.12 being the most critical (Epstein 1997).

The incidence of seizures in DS individuals is estimated as 5-10% (Tatsuno *et al.* 1984, Pueschel *et al.* 1991). However, there seems to be an age-related incidence of epilepsy, with peaks respectively within the first 12 months,

and in the fourth and fifth decades of life (Veall 1974). The first peak may be related to early medical complications (Silva et al. 1996), while the second peak coincides with the development of the neuropathological, Alzheimerlike, changes (Friede 1989). All seizure types may occur in DS, with GTC being the most common (Tatsuno et al. 1984, Pueschel et al. 1991, Stafstrom et al. 1991). Infantile spasms (IS) in DS are 8-10 times more common than in the general population (Stafstrom and Konkol 1994). Prognosis of IS is usually good with regard to both seizure control and cognition. Remission is obtained with ACTH or steroids, without relapse of seizures (Guerrini et al. 1989) and, if later seizure types occur, they are usually of the idiopathic age-related variety (Silva et al. 1996). An exception to such a favourable trend is represented by infantile spasms following a perinatal hypoxic injury (Stafstrom and Konkol 1994, Guerrini et al. 1993).

Reflex seizures, in the context of a startle epilepsy, seem to be particularly frequent in DS (Gimenez-Roldan and Martin 1980, Sàenz-Lope *et al.* 1984, Guerrini *et al.* 1990, Pueschel and Louis 1993). Age at seizure onset is variable, with no evidence of etiological factors other than DS. Most individuals present "pure" forms of reflex epilepsy, with almost all seizures being precipitated by acoustic or tactile stimuli.

Lennox-Gastaut syndrome, although rare, has been well documented in DS. Its *de novo* occurrence at a mean age of 10 seems quite distinctive (Guerrini *et al.* 1993). Lennox-Gastaut syndrome rarely follows infantile spasms. Febrile seizures are uncommon (Tatsuno *et al.* 1984, Stafstrom *et al.* 1991, Guerrini *et al.* 1986, Guerrini *et al.* 1993).

DS brains look smaller, with fronto-temporal lobe hypoplasia, a reduced hindbrain/cerebrum ratio, and a narrowed superior temporal gyrus (Jerrigan *et al.* 1993). Cortical dysgenesis with fewer GABAergic interneurons has been observed (Wisniewski *et al.* 1984). These structural brain abnormalities may play a role in the occurrence of epilepsy in DS, in association with other factors, such as intrinsic physiological alterations or neurochemical processes affecting synaptic transmission.

Fragile X syndrome

Fragile X syndrome is the most common inherited cause of mental retardation, and represents 30% of all cases of X-linked mental retardation (Sherman 2002). It is caused by a trinucleotide repeat expansion of the three bases cytosine-guanine-guanine (CGG) occurring in the *FMR1* gene at Xq27.3. An expansion > 230 CGG repeats (full mutation) is associated with the syndrome. Smaller expansion of 55-200 CGG repeats (premutation) is usually not associated with cognitive impairment, and has been detected in 1 in 259 females, and in 1 in 813 males in the general population (Rousseau *et al.* 1995, Dombrowski *et*

al. 2002). The overall prevalence of fragile X syndrome in males and females may be estimated as 1 in 2,000 to 1 in 3,000 (Sherman 2002). The classical phenotype is characterised by long face; large, prominent ears; prognathism; high-arched palate; hyperextensible fingers; mitral valve prolapse; macroorchidism (postpubertally); flat feet; hypotonia. Females are less affected than males, since they have two X chromosomes, and the normal X is producing a normal amount of FMR1 protein (FMRP), depending on the X inactivation ratio. In both sexes the level of FMRP correlates with the degree of cognitive involvement (Tassone et al. 1999). Most individuals with the premutation have normal cognition (Hagerman et al. 1996, Tassone et al. 2000). In males with the full mutation that is fully methylated (FMR1 not expressed), little or no FMRP is produced. The average IQ in adulthood of full mutation males with > 50% of the cells unmethylated is about 88, and the average IQ of individuals with a mosaic pattern (some cells with the premutation and some cells with the full mutation) is 60 (Hagerman 2002). Almost 70% of full mutation females will have a borderline cognitive delay (IQ 70-84) or a mild mental retardation (IQ 50/55-70). Hyperactivity, attention problems, anxiety (social anxiety), and obsessive-compulsive behaviour are quite common. The diagnosis of fragile X syndrome is confirmed by DNA testing using Southern blot analysis, which determines the CGG repeat number within the FMR1 gene. Polymerase chain reaction (PCR) testing will give a more exact CGG repeat number within the premutation range (Brown 2002).

A point mutation within *FMR1*, leading to an abnormally functioning FMRP, has been described in only a few individuals. Deletion of the *FMR1* gene also causes a typical fragile X phenotype (Hagerman *et al.* 2005).

Seizures are observed in almost 20-25% of subjects with fragile X syndrome (Wisniewski *et al.* 1991, Musumeci *et al.* 1991). They usually occur in childhood, resolve by adolescence, and are well controlled by antiepileptic drugs (Guerrini *et al.* 1989, Wisniewski *et al.* 1991, Musumeci *et al.* 1991, Guerrini *et al.* 1992). The seizure types most frequently observed are generalized tonic-clonic, complex partial, or focal motor (Guerrini *et al.* 1989). Background EEG activity may be slow, and, possibly age-related, mid-temporal spikes (similar to those of benign rolandic epilepsy) have been described in a few males, with or without seizures (Guerrini *et al.* 1989, Wisniewski *et al.* 1991, Musumeci *et al.* 1991).

Klinefelter (XXY) syndrome

The incidence of Klinefelter syndrome (KS) is 1.2 per 1,000 live-born males (Hook *et al.* 1992). The additional X chromosome has been shown to be paternally derived in 50-60% of cases, and maternally derived in 40-50% (Lorda-Sanchez *et al.* 1992). When paternally derived, X-Y

nondisjunction must occur in meiosis I; and when maternally derived, nondisjunction occurs in meiosis I in 48% and in meiosis II in 29% of cases; 16% show postzigotic origin, and in 7% the origin is unknown (Lorda-Sanchez *et al.* 1992, Thomas *et al.* 2000). Maternal age is increased, whereas paternal age is not (Thomas *et al.* 2000, Shi *et al.* 2002). Small testes, gynecomastia, and hypergonadotropic hypogonadism are typical, and some degree of learning disability is usually present. Some individuals are tall and thin with a eunucoid appearance.

The prevalence of seizures in KS is estimated as 2-10% (Becker *et al.* 1966, Nielsen and Pedersen 1969, Genton *et al.* 1992, Guerrini *et al.* 1997). Different seizure types have been observed, such as early-onset febrile seizures (Elia *et al.* 1995); absence seizures and/or generalized tonic-clonic seizures, with 3 Hz spike/wave on the EEG (Genton *et al.* 1992, Bolthauser *et al.* 1978, Battaglia [unpublished observation]). Overall, the majority of individuals have partial epilepsy, usually well controlled by the antiepileptic drugs (Guerrini *et al.* 1997).

Conclusion

We discussed ten, disparate, chromosomal disorders, most of which feature seizures as an important part of its phenotype. Until now, the study of individuals with chromosomal rearrangements associated with epilepsy has been insufficiently explored. In these syndromes, there is an obvious diversity of epilepsy, with a wide spectrum of seizure severity and a wide range of seizure mechanisms. Nevertheless, quite a number of syndromes show a fairly distinctive electro-clinical pattern, apparently linked to the underlying gene disruption. A thorough study of larger samples of such cases, with a better characterisation of seizures, together with the constantly increasing sophistication of molecular cytogenetics, may prove to be of paramount importance for the identification of epilepsy genes.

References

Aguglia U, Le Piane E, Gambardella A, *et al.* Emotion-induced myoclonic absence-like seizures in a patient with inv-dup(15) syndrome: a clinical, EEG, and molecular genetic study. *Epilepsia* 1999; 40: 1316-9.

Allen TL, Brothman AR, Carey JC, Chance PF. Cytogenetic and molecular analysis in trysomy 12p. *Am J Med Genet* 1996; 63: 250-6.

Angelman H. "Puppet" children: a report on three cases. *Dev Med Child Neurol* 1965; 7: 681-3.

Battaglia A, Carey JC, Cederholm P, Viskochil DH, Brothman AR, Galasso C. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. *Pediatrics* 1999a; 103: 830-6. Battaglia A, Carey JC, Cederholm P, Viskochil DH, Brothman AR, Galasso C. Storia naturale della sindrome di Wolf-Hirschhorn: esperienza con 15 casi. *Pediatrics* 1999b; 11: 236-42; (edizione italiana-Milano).

Battaglia A, Carey JC, Wright TJ. Wolf-Hirschhorn (4p-) syndrome. *Adv Pediatr* 2001; 48: 75-113.

Battaglia A, Carey JC, Wright TJ. Wolf-Hirschhorn syndrome. In: GeneReviews: Genetic Disease Online Reviews at GeneTests – GeneClinics (database online). Copyright. Seattle: University of Washington, 2002-2004; (Available at: http://www.geneclinics.org).

Battaglia A, Carey JC. Health supervision and anticipatory guidance of individuals with Wolf-Hirschhorn syndrome. *Am J Med Genet* 1999; 89: 111-5; (Semin Med Genet).

Battaglia A, Carey JC. Natural history of seizures and EEG patterns in Wolf-Hirschhorn (4p-) syndrome. *In preparation*.

Battaglia A, Carey JC. Seizure and EEG patterns in Wolf-Hirschhorn (4p-) syndrome. *Brain Dev* 2005; 27: 362-4.

Battaglia A, Carey JC. Update on the clinical features and natural history of Wolf-Hirschhorn syndrome (WHS): experience with 48 cases. *Am J Hum Genet* 2000; 6: 127.

Battaglia A, Gurrieri F, Bertini E, *et al.* The inv dup(15) syndrome: a clinically recognizable syndrome with altered behaviour, mental retardation and epilepsy. *Neurology* 1997; 48: 1081-6.

Battaglia A, Gurrieri F. Case of apparent Gurrieri syndrome showing molecular findings of Angelman syndrome. *Am J Med Genet* 1999; 82: 100.

Battaglia A, Viskochil DH, Lewin SO, *et al.* 1p deletion syndrome: further clinical characterisation of a common, important and often missed cause of developmental delay/mental retardation. *Proceed Greenwood Genet Ctr* 2004; 23: 140-1.

Battaglia A. Del 1p36 syndrome: a newly emerging clinical entity. *Brain Dev* 2005a; 27: 358-61.

Battaglia A. Sindrome di Wolf-Hirschhorn (4p-): una causa di ritardo mentale grave di difficile diagnosi. *Riv Ital Pediatr* 1997; 23: 254-9; (I]P).

Battaglia A. Wolf-Hirschhorn (4p-) syndrome. In: Cassidy SB, Allanson JE, eds. *Management of Genetic Syndromes*. Hoboken: John Wiley & Sons Inc, 2005b: 667-76.

Battaglia A. The inv dup(15) or idic(15) syndrome: a clinically recognisable neurogenetic disorder. *Brain Dev* 2005c; 27: 365-9.

Becker KL, Hoffman DL, Albert A, Underdahl LO, Mason HL. Klinefelter's syndrome: clinical and laboratory findings in 50 patients. *Arch Intern Med* 1966; 118: 314-21.

Biegel JA, White PS, Marshall HN. Constitutional 1p36 deletion in a child with neuroblastoma. *Am J Hum Genet* 1993; 52: 176-82.

Biraben A, Odent S, Lucas J, *et al.* Chromosome 20 en anneau et épilepsie: diversité des crises étudiées en vidéo-EEG. Un mécanisme sous-cortical d'épileptogénèse est-il au premier plan? *Epilepsies* 2001; 13: 9-15.

Blennow E, Bui TH, Wallin A, Kogner P. Monosomy 1p36.31-33->pter due to a paternal reciprocal translocation: prognostic significance of FISH analysis. *Am J Med Genet* 1996; 65: 60-7.

Blennow E, Nielsen KB, Telenius H, *et al.* Fifty probands with extra structurally abnormal chromosomes characterized by fluorescence in situ hybridization. *Am J Med Genet* 1995; 55: 85-94.

Bolthauser E, Meyer M, Deonna T. Klinefelter's syndrome and neurological disease. *J Neurol* 1978; 219: 253-9.

Borgatti R, Piccinelli P, Passoni D, *et al.* Relationship between clinical and genetic features in 'inverted duplicated chromosome 15' patients. *Pediatr Neurol* 2001; 24: 111-6.

Bower BD, Jeavons PM. The "happy puppet" syndrome. *Arch Dis Childh* 1967; 42: 298-302.

Boyd SG, Harden A, Patton MA. The EEG in early diagnosis of the Angelman (happy puppet) syndrome. *Eur J Pediatr* 1988; 147: 508-13.

Brandt CA, Kierkegaard O, Hindkjaer J, Jensen PKA, Pedersen S, Therkelsen AJ. Ring chromosome 20 with loss of telomeric sequences detected by multicolour PRINS. *Clin Genet* 1993; 44: 26-31.

Brown WT. The molecular biology of the fragile X mutation. In: Hagerman RJ, Hagerman PJ, eds. *3rd ed. Fragile X syndrome: Diagnosis, treatment and research.* Baltimore: Johns Hopkins University Press, 2002: 110-35.

Buckle VJ, Fujita N, Ryder-Cook AS, *et al.* Chromosomal localization of GABA(A) receptor beta-a-3-subunit gene. *Neuron* 1989; 3: 647-54.

Cabrera JC, Marti M, Toledo L, Gine R, Vazquez C. West's syndrome associated with inversion duplication of chromosome 15. *Rev Neurol (Spain)* 1998; 26: 77-9.

Canevini MP, *et al.* Chromosome 20 ring: a chromosomal disorder associated with a particular electroclinical pattern. *Epilepsia* 1998; 39: 942-51.

Centerwall WR, Thompson WP, Allen IE, Fobes CD. Translocation 4p- syndrome. *Am J Dis Child* 1975; 129: 366-70.

Cheng SD, Spinner NB, Zackai EH, Knoll JH. Cytogenetic and molecular characterization of inverted duplicated chromosomes 15 from 11 patients. *Am J Hum Genet* 1994; 55: 753-9.

Chifari R, Guerrini R, Pierluigi M, et al. Mild generalized epilepsy and developmental disorder associated with large inv dup(15). *Epilepsia* 2002; 43: 1096-100.

Cooper H, Hirschhorn K. Apparent deletion of short arms of one chromosome (4 or 5) in a child with defects of midline fusion. *Mammalian Chrom Nwsl* 1961; 4: 14.

Dalla Bernardina B, Zullini E, Fontana E, Colamaria V, Cappellaro O, Avesani E. Sindrome di Angelman: studio EEG-poligrafico di 8 casi. *Boll Lega It Epil* 1992: 257-9; (79/80).

Dallapiccola B, Mandich P, Bellone E, *et al.* Parental origin of chromosome 4p deletion in Wolf-Hirschhorn syndrome. *Am J Med Genet* 1993; 47: 921-4.

De Grouchy J, Turleau C. *Clinical atlas of human chromosomes. 2nd ed.* New York: John Wiley, 1984.

Dombrowski C, Levesque ML, Morel ML, Roulliard P, Morgan K, Rousseau F. Premutation and intermediate-size *FMR1* alleles in 10,572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. *Hum Mol Genet* 2002; 11: 371-8.

Donlon TA, Lalande M, Wyman A, Bruns G, Latt SA. Isolation of molecular probes associated with the chromosome 15 instability in the Prader-Willi syndrome. *Proc Natl Acad Sci USA* 1986; 83: 4408-12.

Elia M, Guerrini R, Musumeci SA, Bonanni P, Gambardella A, Aguglia U. Myoclonic absence-like seizures and chromosome abnormality syndromes. *Epilepsia* 1998; 39: 660-3.

Elia M, Musumeci SA, Ferri R, Scuderi C, Del Gracco S, Stefanini MC. Seizures in Klinefelter's syndrome: a clinical and EEG study of five patients. *Ital J Neurol Sci* 1995; 16: 231-8.

Endele S, Fuhry M, Pak SJ, Zabel BU, Winterpacht A. *LETM1*, a novel gene encoding a putative EF-Hand Ca-binding protein, flanks the Wolf-Hirschhorn syndrome (WHS) critical region and is deleted in most WHS patients. *Genomics* 1999; 60: 218-25.

Epstein CJ. Down syndrome. In: Rosenberg RN, Prusiner SB, Di Mauro S, Barchi RL, eds. *The molecular and genetic basis of neurological diseases*. Boston: Butterworth-Heinemann, 1997: 51-79.

Estabrooks LL, Lamb AN, Aylsworth AS, Callanan NP, Rao KW. Molecular characterization of chromosome 4p deletions resulting in Wolf-Hirschhorn syndrome. *J Med Genet* 1994; 31: 103-7.

Eugster EA, Berry SA, Hirsch B. Mosaicism for deletion 1p36.33 in a patient with obesity and hyperphagia. *Am J Med Genet* 1997; 70: 409-12.

Faivre L, Morichon-Delvallez N, Vior G, *et al.* Prenatal detection of a 1p36 deletion in a fetus with multiple malformations and a review of the literature. *Pren Diagn* 1999; 19: 49-53.

Friede RL. *Developmental neuropathology. 2th ed.* Berlin Heidelberg: Springer-Verlag, 1989.

Fryns JP, Kubien E, Kleczkowska A, *et al.* Ring chromosome 14: a distinct clinical entity. *J Hum Genet* 1983; 31: 367-75.

Genton P, Medina MT, Roger J, Murcia de Medina M, Mattei MG, Guerrini R. Syndrome de Klinefelter (dysgénésie gonadique avec caryotype 47, XXY) et épilepsie: 5 observations. *Boll Lega It Epil* 1992: 69-70; (79/80).

Gillberg C, Steffenburg S, Wahlstrom J, *et al.* Autism associated with marker chromosome. *J Am Acad Child Adolesc Psychiat* 1991; 30: 489-94.

Gimenez-Roldan S, Martin M. Startle epilepsy complicating Down syndrome during adulthood. *Ann Neurol* 1980; 7: 78-80.

Giraudeau F, Aubert D, Young I, et al. Molecular cytogenetic detection of a deletion of 1p36.3. J Med Genet 1997; 34: 314-7.

Gorlin RJ, Cohen MM, Levin LS. In: *Syndromes of the head and neck*. New York - Oxford: Oxford University Press, 1990: 46-8.

Gottfried M, Lavine L, Roessmann U. Neurpathological findings in Wolf-Hirschhorn (4p-) syndrome. *Acta Neuropathol (Berl)* 1981; 55: 163-5.

Guerrini R, Battaglia A, Mattei MG, *et al.* Epilessia e crisi epilettiche nella sindrome del cromosoma X fragile. *Boll Lega It Epil* 1992: 73-4; (79/80).

Guerrini R, Battaglia A, Stagi P, *et al.* Caratteristiche elettrocliniche dell'epilessia nella Sindrome di Down. *Boll Lega It Epil* 1989: 317-9; (66/67).

Guerrini R, Bureau M, Mattei MG, Battaglia A, Galland MC, Roger J. Trisomy 12p syndrome: a chromosomal disorder associated with generalized 3-Hz spike and wave discharges. *Epilepsia* 1990; 31: 557-66.

Guerrini R, Carrozzo R, Rinaldi R. Bonanni P. Angelman Syndrome: Etiology, Clinical Features, Diagnosis and Management of Symptoms. *Pediatric Drugs* 2003; 10: 647-51. Guerrini R, De Lorey TM, Bonanni P, *et al.* Cortical myoclonus in Angelman syndrome. *Ann Neurol* 1996; 40: 39-48.

Guerrini R, Dravet C, Ferrari AR, *et al.* Evoluzione dell'epilessia nelle più frequenti forme genetiche con ritardo mentale. (sindrome di Down e sindrome dell'X fragile). *Ped Med Chir* 1993; 15: 19-22; (Med Surg Ped).

Guerrini R, Genton P, Bureau M, Dravet C, Roger J. Reflex seizures are frequent in patients with Down syndrome and epilepsy. *Epilepsia* 1990; 31: 406-17.

Guerrini R, Gobbi G, Genton P, Bonanni P, Carrozzo R. Chromosomal abnormalities. In: Engel J, Pedley T, eds. *Epilepsy-Vol.3*. Philadelphia-New York: Lippincott-Raven, 1997: 2533-46.

Guthrie RD, Aase JM, Asper AC, Smith D. The 4p- syndrome. *Am J Dis Child* 1971; 122: 421-5.

Hagerman RJ, Staley LW, O' Conner R, *et al*. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. *Pediatrics* 1996; 97: 122-6.

Hagerman RJ. Fragile X syndrome. In: Cassidy SB, Allanson JE, eds. *Management of Genetic Syndromes*. Hoboken: John Wiley & Sons Inc, 2005: 251-63.

Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, eds. *3rd ed. Fragile X syndrome: Diagnosis, treatment and research.* Baltimore: Johns Hopkins University Press, 2002: 3-109.

Hain D, Leversha M, Campbell N. The ascertainment and implications of an unbalanced translocation in the neonate: Familial 1: 15 translocation. *Austr Paediatr J* 1980; 16: 196-200.

Heilstedt HA, Ballif BC, Howard LA, *et al.* Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterisation of the syndrome. *Am J Hum Genet* 2003; 72: 1200-12.

Heilstedt HA, Burgess DL, Anderson AE, *et al.* Loss of the potassium channel β -subunit gene, *KCNAB2*, is associated with epilepsy in patients with 1p36 deletion syndrome. *Epilepsia* 2001; 42: 1103-11.

Holmes GL. Genetics of epilepsy. In: Holmes GL, ed. *Diagnosis and management of seizures in children*. Philadelphia: Saunders Company, 1987: 56-71.

Hook EB, Cross K. Extra structurally abnormal chromosomes (ESAC) detected at amniocentesis: frequency in approximately 75,000 prenatal cytogenic diagnoses and associations with maternal and paternal age. *Am J Hum Genet* 1987; 54: 748-56.

Hook EB. Prevalence, risks and recurrence. In: Brock DJ, Ferguson-Smith MA, eds. *Prenatal diagnosis and screening*. London: Churchill Livingstone, 1992: 351-92.

Epileptic Disord Vol. 7, No. 3, September 2005

Inoue Y, Fujiwara T, Matsuda K, *et al.* Ring chromosome 20 and nonconvulsive status epilepticus: A new epileptic syndrome. *Brain* 1997; 120: 939-53.

Jay V, Becker LE, Chan F-W, Perry TL. Puppet-like syndrome of Angelman: a pathologic and neurochemical study. *Neurology* 1991; 41: 416-22.

Jennings MT, Bird TD. Genetic influences in the epilepsies. *Am J Dis Child* 1981; 135: 450-7.

Jerrigan TL, Bellugi U, Sowell E, Doherty S, Hesselink JR. Cerebral morphologic distinctions between Williams and Down syndromes. *Arch Neurol* 1993; 50: 186-91.

Jorde L, Carey JC, Bamshad MJ, White LR. *Medical Genetics*. St. Louis: Mosby, 2003.

Kanazawa O, Irie N, Kawai I. Epileptic seizures in the 4p- syndrome: report of two cases. *Jpn J Psychiatry Neurol* 1991; 45: 653-9.

Keppler-Noreuil KM, Carroll AJ, Finley WH, Rutledge SL. Chromosome1p terminal deletion: report of new findings and confirmation of two characteristic phenotypes. *J Med Genet* 1995; 32: 619-22.

Knight-Jones E, Knight S, Heussler H, Regan R, Flint J, Martin K. Neurodevelopmental profile of a new dysmorphic syndrome associated with submicroscopic partial deletion of 1p36.3. *Dev Med Child Neurol* 2000; 42: 201-6.

Kuenzle C, Steinlin M, Wohlrab G, *et al.* Adverse effects of Vigabatrin in Angelman Syndrome. *Epilepsia* 1998; 39: 1213-5.

Kyriakides T, Hallam LA, Hockey A, Silberstein P, Kakulas BA. Angelman's syndrome: a neuropathological study. *Acta Neuropathol (Berl)* 1992; 83: 675-8.

Laan LAEM, Renier WO, Arts WFM, *et al.* Evolution of epilepsy and EEG findings in Angelman syndrome. *Epilepsia* 1997; 38: 195-9.

Lancman ME, Penry JK, Asconape JJ, Brotherton TA. Number 20 ring chromosome: a case with complete seizure control. *J Child Neurol* 1993; 8: 186-7.

Lazjuk GI, Lurie IW, Ostrowskaja TI, *et al*. The Wolf-Hirschhorn syndrome. II. Pathologic anatomy. *Clin Genet* 1980; 18: 6-12.

Lippe BM, Sparkes RS. Ring 14 chromosome: association with seizures. *Am J Med Genet* 1981; 9: 301-5.

Lorda-Sanchez I, Binkert F, Maechler M, Robinson WP, Schinzel AA. Reduced recombination and paternal age effect in Klinefelter syndrome. *Hum Genet* 1992; 89: 524-30.

Luke S, Verma RS, Giridharan R, Conte RA, Macera MJ. Two Prader-Willi/Angelman syndrome loci present in an isodicentric marker chromosome. *Am J Med Genet* 1994; 51: 232-3.

Lurie IW, Lazjuk GL, Ussova I, Presman EB, Gurevich DB. The Wolf-Hirschhorn syndrome. I. Genetics. *Clin Genet* 1980; 17: 375-84.

Magenis RE, Sheehy R, Lacey D, Brown MG, Litt M. Small terminal deletion of chromosome 1 short arm in an infant with multiple anomalies: confirmation by in situ hybridisation of probe p1-79. *Am J Hum Genet* 1987; 41: A130.

Matalon R, Supple P, Wyandt H, *et al.* Transmission of ring 14 chromosome from mother to two sons. *Am J Med Genet* 1990; 36: 381-5.

Matsumoto A, Kumagai T, Miura K, *et al.* Epilepsy in Angelman syndrome associated with chromosome 15q deletion. *Epilepsia* 1992; 33: 1083-90.

Minassian B, DeLorey T, Olsen RW, *et al.* The epilepsy of Angelman syndrome due to deletion, disomy, imprinting center and UB3A mutations. *Ann Neurol* 1998; 43: 485-93.

Musumeci SA, Ferri R, Elia M, Cologna RM, Bergonzi P, Tassinari CA. Epilepsy and fragile X syndrome: a follow-up study. *Am J Med Genet* 1991; 38: 511-3.

Nielsen J, Pedersen E. Electro-encephalographic findings in patients with Klinefelter's syndrome and the XXY-syndrome. *Acta Neurol Scand* 1969; 45: 87-94.

Nielsen J, Venter M, Holm V, Askjaer SA, Reske-Nielsen E. A newborn child with caryotype 47, XX,+der(12)(12pter> 12q12:8q24 > 8qter), t(8; 12)(q24;q12)pat. *Hum Genet* 1977; 35: 357-62.

Ogle R, Sillence DO, Merrick A, *et al.* The Wolf-Hirschhorn syndrome in adulthood: evaluation of a 24-year-old man with a rec(4) chromosome. *Am J Med Genet* 1996; 65: 124-7.

Petit J, Roubertie A, Inoue Y, *et al.* Non-convulsive status in the ring chromosome 20 syndrome: a video illustration of 3 cases. *Epileptic Disord* 1999; 1: 237-41.

Pueschel SM, Louis S. McKnight P. Seizure disorders in Down syndrome. *Arch Neurol* 1991; 84: 318-20.

Pueschel SM, Louis S. Reflex seizures in Down syndrome. *Childs* Nerv Syst 1993; 9: 23-4.

Ray M, Chudley AE, Christie N, Seargeant L. A case of *de novo* trisomy 12p syndrome. *Ann Genet (Paris)* 1985; 28: 235-8.

Reid I, Morrison N, Barron L, *et al.* Familial Wolf-Hirschhorn syndrome resulting from a *cryptic* translocation: a clinical and molecular study. *J Med Genet* 1996; 33: 197-202.

Reish O, Berry SA, Hirsch B. Partial monosomy of chromosome 1p36.3: characterisation of the critical region and delineation of a syndrome. *Am J Med Genet* 1995; 59: 467-75.

Riegel M, Castellan C, Balmer D, Brecevic L, Schinzel A. Terminal deletion, del(1)(p36.3), detected through screening for terminal deletions in patients with unclassified malformation syndromes. *Am J Med Genet* 1999; 82: 249-53.

Riley SB, Buckton KE, Ratcliffe SG, *et al.* Inheritance of a Ring 14 chromosome. *J Med Genet* 1981; 18: 209-13.

Robinson WP, Binkert F, Gine R, *et al.* Clinical and molecular analysis of five inv dup (15) patients. *Eur J Hum Genet* 1993; 1: 37-50.

Roubertie A, Petit J, Genton P. Chromosome 20 en anneau: un syndrome épileptique identifiable. *Rev Neurol* 2000; 156: 149-53.

Rougelle C, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. *Nat Genet* 1997; 17: 14-5; [letter].

Rousseau F, Roulliard P, Morel ML, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the *FMR1* gene and implications for the population genetics of the fragile X syndrome. *Am J Hum Genet* 1995; 57: 1006-18.

Sàenz-Lope E, Herranz FJ, Marsden JC. Startle epilepsy: a clinical study. *Ann Neurol* 1984; 16: 78-81.

Sandlin CJ, Dodd BS, Dumars KW, Bartley JA, Bernstein R, Lamb A. Phenotypes associated with terminal deletion of the short arm of chromosome 1. *Am J Hum Genet* 1995; 57: A125.

Schinzel A, Niedrist D. Chromosome imbalances associated with epilepsy. *Am J Med Genet* 2001; 106: 119-24; (Semin Med Genet).

Schinzel A. *Catalogue of Unbalanced Chromosome Aberrations in Man.* Berlin-New York: Walter de Gruyter, 2001.

Schmidt R, Eviatar L, Nitowski HM, *et al.* Ring chromosome 14: a distinct clinical entity. *J Med Genet* 1981; 18: 304-7.

Sgrò V, Riva E, Canevini MP, *et al.* 4p- syndrome: a chromosomal disorder associated with a particular EEG pattern. *Epilepsia* 1995; 36: 1206-14.

Shaffer LG, Heilstedt HA. Terminal deletion of 1p36. *Lancet* 2001; 358: S9.

Shapira SK, McCaskill C, Northrup H, *et al.* Chromosome 1p36 deletions: the clinical phenotype and molecular characterisation of a common newly delineated syndrome. *Am J Hum Genet* 1997; 61: 642-50.

Sherman S. Epidemiology. In: Hagerman RJ, Hagerman PJ, eds. *3rd ed. Fragile X syndrome: Diagnosis, treatment and research.* Baltimore: Johns Hopkins University Press, 2002: 136-68.

Shi Q, Spriggs E, Field LL, *et al.* Absence of age effect on meiotic recombination between human X and Y chromosomes. *Am J Hum Genet* 2002; 71: 254-61.

Silva ML, Cieuta C, Guerrini R, Plouin P, Livet MO, Dulac O. Early clinical and EEG features of infantile spasms in Down syndrome. *Epilepsia* 1996; 37: 977-82.

Singh R, McKinley Gardner RJ, Crossland KM, Scheffer IE, Berkovic SF. Chromosomal abnormalities and epilepsy: a review for clinicians and gene hunters. *Epilepsia* 2002; 43: 127-40.

Slavotinek A, Rosenberg M, Knight S, *et al.* Screening for submicroscopic chromosome rearrangements in children with idiopathic mental retardation using microsatellite markers for the chromosome telomeres. *J Med Genet* 1999; 36: 405-11.

Slavotinek A, Shaffer LG, Shapira SK. Monosomy 1p36. J Med Genet 1999; 36: 657-63.

Smith GF, Berg JM. *Down's anomaly. 2nd ed.* Edinburgh: Churchill Livingstone, 1976.

Stafstrom CE, Konkol RJ. Infantile spasms in children with Down syndrome. *Dev Med Chil Neurol* 1994; 36: 576-85.

Stafstrom CE, Patxot CE, Gilmore HE, Wisniewski KE. Seizures in children with Down syndrome: etiology, characteristics and outcome. *Dev Med Child Neurol* 1991; 33: 191-200.

Steffenburg S, Gillberg CL, Steffenburg U, *et al.* Autism in Angelman syndrome: a population-based study. *Pediatr Neurol* 1996; 14: 131-6.

Stengel-Rutkoswki S, Albert A, Murken DJ, *et al.* New chromosomal dysmorphic syndromes. Trisomy 12p. *Eur J Pediatr* 1981; 136: 249-62.

Stengel-Rutkowski S, Warkotsch A, Schimanek P, Stene J. Familial Wolf's syndrome with a hidden 4p deletion by translocation of an 8p segment. Unbalanced inheritance from a maternal translocation (4; 8)(p15.3; p22). Case report, review and risk estimates. *Clin Genet* 1984; 25: 500-21. Sugimoto T, Araki A, Yasuhara A, Woo M, Nishida N, Sasaki T. Angelman syndrome in three siblings: genetic model of epilepsy associated with chromosomal DNA deletion of the GABA^A receptor. *Jpn J Psychiatry Neurol* 1994; 42: 271-3.

Takeda Y, Baba A, Nakamura F, Ito M, Honma H, Koyama T. Symptomatic generalized epilepsy associated with an inverted duplication of chromosome 15. *Seizure* 2000; 9: 145-50.

Tassone F, Hagerman RJ, Ikle D, *et al.* FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am J Med Genet* 1999; 84: 250-61.

Tassone F, Hagerman RJ, Taylor AK, *et al.* Clinical involvement and protein expression in individuals with *FMR1* premutation. *Am J Med Genet* 2000; 91: 144-52.

Tatsuno M, Hayashi M, Iwamoto H, *et al.* Epilepsy in childhood Down syndrome. *Brain Dev* 1984; 6: 37-44.

Thomas NS, Collins AR, Hassold TJ, Jacobs PA. A reinvestigation of non-disjunction resulting in 47, XXY males of paternal origin. *Eur J Hum Genet* 2000; 8: 805-8.

Torrisi L, Sangiorgi E, Russo L, Gurrieri F. Rearrangements of chromosome 15 in epilepsy. *Am J Med Genet* 2001; 106: 125-8; (Semin Med Genet).

Tupler R, Bortotto L, Buhler EM, *et al.* Paternal origin of the de novo deleted chromosome 4 in Wolf-Hirschhorn syndrome. *J Med Genet* 1992; 29: 53-5.

Van Buggenhout G, Melotte C, Dutta B, *et al.* Mild Wolf-Hirschhorn syndrome: micro-array CGH analysis of atypical 4p16.3 deletions enables refinement of the genotype-phenotype map. *J Med Genet* 2004; 41: 691-8.

Veall RM. The prevalence of epilepsy among mongols related to age. *J Ment Def Res* 1974; 18: 99-106.

Viani F, Romeo A, Viri M, *et al.* Seizure and EEG patterns in Angelman's syndrome. *J Child Neurol* 1995; 10: 467-71.

Webb T, Hardy CA, King M, Watkiss E, Mitchell C, Cole T. A clinical, cytogenetic and molecular study of ten probands with inv dup (15) marker chromosomes. *Clin Genet* 1998; 53: 34-43.

Wenger SL, Steele MW, Becker DJ. Clinical consequences of deletion 1p35. *J Med Genet* 1988; 25: 263.

Williams CA. Angelman syndrome. In: Cassidy SB, Allanson JE, eds. *Management of Genetic Syndromes*. Hoboken: John Wiley & Sons Inc, 2005: 53-62.

Wisniewski KE, Laure-Kamionowska M, Wisniewski HM. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down syndrome. *N Engl J Med* 1984: 1187-8.

Wisniewski KE, Segan SM, Miezejesji EA, Sersen EA, Rudelli RD. The Fra (X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. *Am J Med Genet* 1991; 38: 476-80.

Wu YQ, Heilstedt HA, Bedell JA, *et al.* Molecular refinement of the 1p36 deletion syndrome reveals size diversity and a preponderance of maternally derived deletions. *Hum Mol Genet* 1999; 8: 313-21.

Yunis E, Quintero L, Lebovici M. Monosomy 1pter. *Hum Genet* 1981; 56: 279-82.

Zankl A, Addor MC, Maeder-Ingvar M, Schorderet DF. A characteristic EEG pattern in 4p- syndrome: case report and review of the literature. *Eur J Pediatr* 2001; 160: 123-7.

Zelante L, Torricelli F, Calvano S, *et al.* Ring chromosome 14 syndrome: report of two cases, including extended evaluation of a previously reported patient and review. *Ann Genet* 1991; 34: 93-7.

Zollino M, Lecce R, Fischetto R, *et al.* Mapping the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS critical region and defining a new critical region, WHSCR-2. *Am J Hum Genet* 2003; 72: 590-7.

Zori RT, Hendrickson J, Woolven S, *et al.* Angelman syndrome: clinical profile. *J Child Neurol* 1992; 7: 270-80.

Zuberi SM, Biraben AJ. Presentation, clinical evaluation and outcome in ring chromosome 20 syndrome. *Brain Dev* 2004; 26: 554-5 [abstract].